drugset / Trial / NCT05694364
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1
Completed
3 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies.
Timeline
- Start
- 2023-01-25
- Primary completion
- 2024-04-18
- Completion
- 2024-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRGN-3007 | Cell therapy | 1e+06 cells/kg | — |
| Subject | PRGN-3007 | Cell therapy | 3e+06 cells/kg | — |
| Subject | PRGN-3007 | Cell therapy | 1e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |